Datopotamab Deruxtecan vs Sacituzumab Govitecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline

Datopotamab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in Non-Small Cell Lung Cancerantibody-drug conjugate
Partial signal

NCT04656652 · Phase 3 · active, not recruiting

This open-label, randomized Phase III trial (TROPION-Lung01) assigned 604 patients with previously treated advanced or metastatic non-small cell lung cancer to datopotamab deruxtecan or docetaxel. It had two primary endpoints, progression-free survival and overall survival. Progression-free survival improved significantly (hazard ratio 0.75, P=.004), but overall survival showed only a numerical benefit that did not reach statistical significance (hazard ratio 0.94, P=.530). One primary was met and one was missed, so the result is mixed. Source: the peer-reviewed paper (Ahn et al., J Clin Oncol 2025).

Next expected readout: January 2027 · NCT06417814 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel (From randomization until disease progression or death (whichever occurs first), up to approximately 27 months); Overall Survival (OS) Following DS-1062a Versus Docetaxel (From randomization until date of death due to any cause, up to to approximately 38 months): Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025). (mixed)

Result source: NCT04656652

Sacituzumab Govitecan

Marketed by Gilead Sciences and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
Partial signal

NCT05089734 · Phase 3 · active, not recruiting

This was a randomized, open-label Phase 3 trial of 603 patients comparing sacituzumab govitecan to docetaxel, using overall survival (a hard clinical endpoint) as the primary measure. Although the drug showed a numerical survival advantage (11.1 vs 9.8 months), the difference did not reach statistical significance (p=0.0534), so the trial's primary comparison was not formally met despite a reasonably strong and adequately powered design.

Next expected readout: January 2027 · NCT05609968 (registry estimate)

Reported efficacy

Overall Survival (OS) (Up to 24.4 months): EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant (missed)

Result source: NCT05089734

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDatopotamab DeruxtecanSacituzumab Govitecan
PFS, median4.4 vs 3.7vs Docetaxel6.0 mg/kg · n 299NCT04656652
1 other result
  • 4.4 vs 3 6.0 mg/kg · n 299 · Phase 3 · secondary NCT04656652
—Trial running · NCT05609968
OS, median12.9 vs 11.8vs Docetaxel6.0 mg/kg · n 299NCT04656652—Trial running · NCT05609968
ORR35.8%b6.0 mg/kg Q3W · n 137NCT04484142—Trial running · NCT05609968
Duration of response, median—Trial running · NCT04656652—Trial running · NCT05609968

PFS, median

Datopotamab Deruxtecan
4.4 vs 3.7vs Docetaxel6.0 mg/kg · n 299NCT04656652
1 other result
  • 4.4 vs 3 6.0 mg/kg · n 299 · Phase 3 · secondary NCT04656652
Sacituzumab Govitecan
—Trial running · NCT05609968

OS, median

Datopotamab Deruxtecan
12.9 vs 11.8vs Docetaxel6.0 mg/kg · n 299NCT04656652
Sacituzumab Govitecan
—Trial running · NCT05609968

ORR

Datopotamab Deruxtecan
35.8%b6.0 mg/kg Q3W · n 137NCT04484142
Sacituzumab Govitecan
—Trial running · NCT05609968

Duration of response, median

Datopotamab Deruxtecan
—Trial running · NCT04656652
Sacituzumab Govitecan
—Trial running · NCT05609968
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Sacituzumab Govitecan
EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant NCT05089734 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Datopotamab Deruxtecan: 4 of 4 rows · Sacituzumab Govitecan: 1 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDatopotamab DeruxtecanSacituzumab Govitecan
Dropout rate
77.3%6.0 mg/kga
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
85.4%6.0 mg/kg Q3W
NCT04484142 · Phase 2
4.8%10 mg/kgb
NCT01631552 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—6.0 mg/kga
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
9.5%6.0 mg/kg Q3W
NCT04484142 · Phase 2
—10 mg/kgb
NCT01631552 · Phase 1/2 · registry result, not featured evidence
Serious AEs
31%6.0 mg/kga
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
24.8%6.0 mg/kg Q3W
NCT04484142 · Phase 2
—10 mg/kgb
NCT01631552 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
6.0 mg/kga
stomatitis 49.8%
nausea 37.7%
alopecia 32%
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
6.0 mg/kg Q3W
nausea 59.9%
stomatitis 57.7%
alopecia 51.1%
NCT04484142 · Phase 2
—

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Datopotamab Deruxtecan

PFS 4.4 vs 3.7 Docetaxel months6.0 mg/kg
time to event · months
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
4.4 vs 3 Docetaxel months6.0 mg/kg
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 12.9 vs 11.8 Docetaxel months6.0 mg/kg
time to event · months
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 26.4% (n=299) vs 12.8% (n=305) Docetaxel6.0 mg/kg
event count · % of participants
Assessed by Blinded Independent Central Review
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 79 Participants as posted
Duration of Response 7.1 vs 5.6 Docetaxel months6.0 mg/kg
time to event · months
Assessed by Blinded Independent Central Review
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 35.8% (n=137)6.0 mg/kg Q3W
responder rate · % of participants
No placebo or comparator arm
NCT04484142 · Phase 2

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: TROP2 · full HR+/HER2- Metastatic Breast Cancer pipeline

Datopotamab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
Partial signal

NCT05104866 · Phase 3 · active, not recruiting

Patients were randomized (365 vs 367) against active chemotherapy, but the study was open-label with no masking. The two co-primary endpoints disagreed: progression-free survival was significantly better (hazard ratio 0.63, p<0.0001) while overall survival showed no difference (hazard ratio 1.01, p=0.9445).

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months); Overall Survival (From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.): Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) (mixed)

Result source: NCT05104866

Sacituzumab Govitecan

Marketed by Gilead Sciences and partners

Approved in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
Partial signal

NCT03901339 · Phase 3 · completed

The trial was large and randomized, with 272 participants receiving sacituzumab govitecan and 271 receiving active physician’s-choice chemotherapy, and its independently reviewed imaging-based progression-free survival endpoint was met. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the statistically significant result.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) (met)

Result source: NCT03901339

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDatopotamab DeruxtecanSacituzumab Govitecan
PFS, median6.9 vs 4.9vs Investigator's Choice of Chemotherapy (ICC)n 365NCT05104866
1 other result
5.5 vs 4vs Treatment of Physician's Choicen 272NCT03901339
1 other result
OS, median18.6 vs 18.3vs Investigator's Choice of Chemotherapy (ICC)n 365NCT0510486614.5 vs 11.2vs Treatment of Physician's Choicen 272NCT03901339
ORR—Trial running · NCT05104866—Trial running · NCT05840211
Clinical benefit rate—Trial running · NCT05104866—Trial running · NCT05840211

PFS, median

Datopotamab Deruxtecan
6.9 vs 4.9vs Investigator's Choice of Chemotherapy (ICC)n 365NCT05104866
1 other result
Sacituzumab Govitecan
5.5 vs 4vs Treatment of Physician's Choicen 272NCT03901339
1 other result

OS, median

Datopotamab Deruxtecan
18.6 vs 18.3vs Investigator's Choice of Chemotherapy (ICC)n 365NCT05104866
Sacituzumab Govitecan
14.5 vs 11.2vs Treatment of Physician's Choicen 272NCT03901339

ORR

Datopotamab Deruxtecan
—Trial running · NCT05104866
Sacituzumab Govitecan
—Trial running · NCT05840211

Clinical benefit rate

Datopotamab Deruxtecan
—Trial running · NCT05104866
Sacituzumab Govitecan
—Trial running · NCT05840211
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Datopotamab Deruxtecan: 2 of 4 rows · Sacituzumab Govitecan: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDatopotamab DeruxtecanSacituzumab Govitecan
Dropout rate
n/a: no completion milestone
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestone
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Discontinued due to AEs
—
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Serious AEs
17.2%
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
27.6%
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Most frequent reported AEs
nausea 56.7%
stomatitis 52.2%
alopecia 37.8%
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 68.7%
diarrhoea 60.8%
nausea 58.6%
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Datopotamab Deruxtecan

ORR 36.44% (n=365) vs 22.89% (n=367) Investigator's Choice of Chemotherapy (ICC)
responder rate · % of participants
Confirmed response by BICR assessment based on IA1 data cut-off Raw Response Rate (%)
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 6.7 vs 5.7 Investigator's Choice of Chemotherapy (ICC) months
time to event · months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
7.2 vs 6 Investigator's Choice of Chemotherapy (ICC) months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Sacituzumab Govitecan

ORR 21.3% (n=272) vs 14% (n=271) Treatment of Physician's Choice
responder rate · % of participants
ORR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 8.1 vs 5.6 Treatment of Physician's Choice months
time to event · months
DOR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 33.8% (n=272) vs 22.1% (n=271) Treatment of Physician's Choice
responder rate · % of participants
CBR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Breast Cancer

Shared mechanism: TROP2 · full Breast Cancer pipeline

Datopotamab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in Breast Cancerantibody-drug conjugate
Partial signal

NCT05104866 · Phase 3 · active, not recruiting

Patients were randomized (365 vs 367) against active chemotherapy, but the study was open-label with no masking. The two co-primary endpoints disagreed: progression-free survival was significantly better (hazard ratio 0.63, p<0.0001) while overall survival showed no difference (hazard ratio 1.01, p=0.9445).

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months); Overall Survival (From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.): Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) (mixed)

Result source: NCT05104866

Sacituzumab Govitecan

Marketed by Gilead Sciences and partners

Approved in Breast Cancerantibody-drug conjugate
Partial signal

NCT03901339 · Phase 3 · completed

The trial was large and randomized, with 272 participants receiving sacituzumab govitecan and 271 receiving active physician’s-choice chemotherapy, and its independently reviewed imaging-based progression-free survival endpoint was met. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the statistically significant result.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) (met)

Result source: NCT03901339

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Datopotamab Deruxtecan: 4 of 6 rows · Sacituzumab Govitecan: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDatopotamab DeruxtecanSacituzumab Govitecan
Overall Survival
time to event · months
18.6 vs 18.3 Investigator's Choice of Chemotherapy (ICC) monthsa,b,c
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
14.5 vs 11.2 Treatment of Physician's Choice monthsa,b,c
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
2 other source trials
12.1 vs 6.7 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
11.8 vs 6.9 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
PFS
time to event · months
6.9 vs 4.9 Investigator's Choice of Chemotherapy (ICC) monthsd,a,b,c
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
6.9 vs 4.5 Investigator's Choice of Chemotherapy (ICC) months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
5.5 vs 4 Treatment of Physician's Choice monthsd,a,b,c
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
4.3 vs 3.1 Treatment of Physician's Choice months
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Dropout rate
n/a: no completion milestone
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestonee
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 2 more results
n/a: no completion milestone
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
4.8%10 mg/kg
NCT01631552 · Phase 1/2
Discontinued due to AEs
—
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—e
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 2 more results
—
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
—10 mg/kg
NCT01631552 · Phase 1/2
Serious AEs
17.2%
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
27.6%e
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 2 more results
26.7%
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
—10 mg/kg
NCT01631552 · Phase 1/2
Most frequent reported AEs
nausea 56.7%
stomatitis 52.2%
alopecia 37.8%
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
e
neutropenia 68.7%
diarrhoea 60.8%
nausea 58.6%
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
diarrhoea 65.1%
nausea 62%
fatigue 51.6%
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3

Notes

  1. aPopulation context differs: baseline_threshold differs (lvef>=50 versus none recorded); prior_therapy differs (none recorded versus experienced).
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Datopotamab Deruxtecan

ORR 36.44% (n=365) vs 22.89% (n=367) Investigator's Choice of Chemotherapy (ICC)
responder rate · % of participants
Confirmed response by BICR assessment based on IA1 data cut-off Raw Response Rate (%)
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 6.7 vs 5.7 Investigator's Choice of Chemotherapy (ICC) months
time to event · months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
7.2 vs 6 Investigator's Choice of Chemotherapy (ICC) months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Sacituzumab Govitecan

ORR 21.3% (n=272) vs 14% (n=271) Treatment of Physician's Choice
responder rate · % of participants
ORR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 8.1 vs 5.6 Treatment of Physician's Choice months
time to event · months
DOR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 33.8% (n=272) vs 22.1% (n=271) Treatment of Physician's Choice
responder rate · % of participants
CBR by BICR Assessment
NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 34.9% (n=235) vs 4.7% (n=233) Treatment of Physician's Choice (TPC)
responder rate · % of participants
ORR by IRC Assessment
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
Time to Response 2.14 vs 2.72 Treatment of Physician's Choice (TPC) months
time to event · months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
show 1 more result
2.67 vs 1.86 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
Duration of Response 6.3 vs 3.6 Treatment of Physician's Choice (TPC) months
time to event · months
IRC Assessment
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
Time to Progression 5.7 vs 1.8 Treatment of Physician's Choice (TPC) months
time to event · months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
show 1 more result
5.8 vs 2.1 Treatment of Physician's Choice (TPC) months
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
Clinical Benefit 44.7% (n=235) vs 8.6% (n=233) Treatment of Physician's Choice (TPC)
responder rate · % of participants
IRC Assessment
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
EORTC QLQ-C30 Global Health Status -5.8 vs -9.4 Treatment of Physician's Choice (TPC) score
absolute change · score
Global Health Status/QoL: Change From Baseline at EOT
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
EORTC QLQ-C30 Physical Functioning -4.6 vs -13.5 Treatment of Physician's Choice (TPC) score
absolute change · score
Physical Functioning: Change From Baseline at EOT
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
EORTC QLQ-C30 Role Functioning -8.4 vs -18.8 Treatment of Physician's Choice (TPC) score
absolute change · score
Role Functioning: Change From Baseline at EOT
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3
EORTC QLQ-C30 Emotional Functioning -3.8 vs -3.5 Treatment of Physician's Choice (TPC) score
absolute change · score
Emotional Functioning: Change From Baseline at EOT
NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3

+ 11 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Datopotamab Deruxtecan's landscape · Sacituzumab Govitecan's landscape